VCAN Is Essential for ERK5-Driven Tumorigenesis in Soft Tissue Sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The ERK5 signaling pathway is increasingly recognized for its role in soft tissue sarcoma (STS) development and progression.
• Understanding the molecular mechanisms underlying ERK5's function in STS is crucial for identifying new therapeutic strategies.

Purpose of the Study:

• To identify novel downstream targets of ERK5 in STS.
• To elucidate the role of VCAN (a chondroitin sulfate proteoglycan) as a mediator of ERK5-driven oncogenesis in STS.

Main Methods:

• Utilized genetic manipulation (shRNA silencing, overexpression) and pharmacological inhibition of ERK5 in murine sarcoma models and human STS cell lines.
• Performed transcriptomic profiling to assess VCAN's contribution to the ERK5 gene expression program.
• Analyzed VCAN and ERK5 expression in human STS patient samples (leiomyosarcomas, undifferentiated pleomorphic sarcomas) and normal tissues.

Main Results:

• Identified VCAN as a novel transcriptional target of ERK5, with ERK5 positively regulating VCAN expression.
• Demonstrated that VCAN silencing phenocopies ERK5 silencing effects (impaired migration, adhesion, proliferation, tumorigenesis), while VCAN overexpression rescues these effects.
• Found significantly elevated VCAN and ERK5 mRNA levels in human STS tissues compared to normal tissues, with a strong correlation between VCAN and ERK5 expression in specific STS subtypes.

Conclusions:

• VCAN is a key effector in ERK5-mediated tumorigenesis and oncogenesis in soft tissue sarcomas.
• The ERK5/VCAN signaling axis represents a promising therapeutic target for soft tissue sarcomas.